Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Malondialdehyde-Modified LDL as a Marker of Acute Coronary Syndromes

Article Abstract:

Measuring blood levels of malondialdehyde (MDA)-modified low-density lipoprotein (LDL) and myocardial troponin I may distinguish patients with stable coronary artery disease (CAD) and those with unstable angina or a heart attack. MDA-LDL and troponin I are produced by damage to the heart. In a study of 104 patients with a history of CAD, the production of MDA-LDL and troponin I was 98% accurate in detecting patients with unstable angina and 100% accurate in diagnosing a heart attack. The absence of MDA-LDL and troponin was 99% accurate in detecting patients with stable CAD.

Author: Collen, Desire, Werf, Frans Van de, Holvoet, Paul
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
Diagnosis, Unstable angina, Low density lipoproteins

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Troponins in acute coronary syndromes: More tactics for an early invasive strategy

Article Abstract:

Patients with symptoms of a heart attack who also have increased blood levels of cardiac troponins have a high risk of death and should be treated with angioplasty. Troponins are proteins produced by the heart when it is damaged. However, the tests for troponin can produce different results, and many medical conditions can cause a false-negative or false-positive result.

Author: Moliterno, David J., Quinn, Martin J.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Health aspects, Editorial, Physiological aspects

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Healing achilles-sirolimus versus paclitaxel

Article Abstract:

The findings from randomized, head-to-head comparisons of a sirolimus-eluting stent with a paclitaxel-eluting stent are presented. The data overall from randomized clinical trials and from registries suggests that the currently available sirolimus-eluting stents provide an angiographic and clinical edge over the currently available paclitaxel-eleuting stents.

Author: Moliterno, David J.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
Product information, Testing, Clinical trials, Paclitaxel, Sirolimus

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Heart attack, Muscle proteins
Similar abstracts:
  • Abstracts: Biologic modifiers and chemoprevention of cancer of the oral cavity. DNA content as a prognostic marker in patients with oral leukoplakia
  • Abstracts: Catabolic illness: strategies for enhancing recovery. Occupational illness. High-altitude illness
  • Abstracts: Vitamin A Deficiency Among Children--Federated States of Micronesia, 2000. Kernicterus in Full-Term Infants--United States, 1994-1998
  • Abstracts: Oral galvanism in Sweden. Oral cancer growth factor found
  • Abstracts: The changing face of infectious disease: New threats, new science. Leukemia: steady progress brightens outlook on blood disease
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.